CN103520234A - 太白楤木总皂苷提取物的新用途 - Google Patents
太白楤木总皂苷提取物的新用途 Download PDFInfo
- Publication number
- CN103520234A CN103520234A CN201310504888.8A CN201310504888A CN103520234A CN 103520234 A CN103520234 A CN 103520234A CN 201310504888 A CN201310504888 A CN 201310504888A CN 103520234 A CN103520234 A CN 103520234A
- Authority
- CN
- China
- Prior art keywords
- cortex araliae
- araliae chinensis
- arthritis
- medicine
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 56
- 150000007949 saponins Chemical class 0.000 title claims abstract description 56
- 239000000284 extract Substances 0.000 title claims abstract description 21
- 241000722818 Aralia Species 0.000 title claims abstract description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 title abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 208000009386 Experimental Arthritis Diseases 0.000 claims abstract description 16
- 206010003246 arthritis Diseases 0.000 claims abstract description 16
- 201000005569 Gout Diseases 0.000 claims abstract description 14
- 206010018634 Gouty Arthritis Diseases 0.000 claims abstract description 14
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 12
- 235000017709 saponins Nutrition 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 241001529246 Platymiscium Species 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000857 drug effect Effects 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 2
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 231100000989 no adverse effect Toxicity 0.000 abstract 1
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 241000700159 Rattus Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 210000000845 cartilage Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 210000001258 synovial membrane Anatomy 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 210000000629 knee joint Anatomy 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 9
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 9
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 9
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229940100243 oleanolic acid Drugs 0.000 description 9
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000011010 flushing procedure Methods 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-Butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 241000283977 Oryctolagus Species 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 102000055008 Matrilin Proteins Human genes 0.000 description 4
- 108010072582 Matrilin Proteins Proteins 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- KXPKWHNZKVLCRR-UHFFFAOYSA-N 6-aminopyrimidine-4-carboxylic acid Chemical compound NC1=CC(C(O)=O)=NC=N1 KXPKWHNZKVLCRR-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241001438332 Aralia decaisneana Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009916 joint effect Effects 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000167549 Aralia chinensis Species 0.000 description 1
- 244000015024 Aralia cordata var. sachalinensis Species 0.000 description 1
- 241000977348 Aralia echinocaulis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 0 CC(C)(C(CC1)C(C)(CC2)C3C1(C)[C@](C)(CCC1(*)C4C*(C)(C)CC1)C4=CC3)C2O* Chemical compound CC(C)(C(CC1)C(C)(CC2)C3C1(C)[C@](C)(CCC1(*)C4C*(C)(C)CC1)C4=CC3)C2O* 0.000 description 1
- UUFPWVIQCLRJER-UHFFFAOYSA-N CCCC(CC1)C(C)(C)C(CC2)C1(C)C1C2(C)C(C)(CCC2(C3CCCC2)O)C3=CC1 Chemical compound CCCC(CC1)C(C)(C)C(CC2)C1(C)C1C2(C)C(C)(CCC2(C3CCCC2)O)C3=CC1 UUFPWVIQCLRJER-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000998584 Nuda Species 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- -1 ester glycosides Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了太白楤木总皂苷提取物在制备治疗关节炎的药物中的用途。本发明还提供了楤木皂苷A的新用途。本发明药物用于治疗佐剂性关节炎、骨关节炎、痛风性关节炎，药效明确。本发明药物属于纯天然制剂，不经有机溶剂处理，安全可靠；毒性小，长期使用无不良反应；对各种原因引起的关节炎均有预防和治疗作用。
Description
技术领域
本发明涉及太白楤木总皂苷提取物的新用途。
背景技术
五加科楤木属(Aralia Linn1)植物,全世界共有40余种,大多数分布于亚洲和北美，我国广泛分布28种，其中20种可供药用。楤木属一些植物芽苞及嫩叶富含蛋白质、氨基酸、维生素、粗纤维和胡萝卜素等,是高档山野菜,素有“山菜之王”的美誉。目前对楤木属植物研究主要是辽东楤木(A.schmidtii Pojark)、黄毛楤木（Aralia decaisneana Hance）、棘茎楤木(Aralia echinocaulis Hand.Mazz)、太白楤木、白背叶楤木（Var.nuda Nakai）等。楤木(Aralia chinensis)在我国分布广泛，太白楤木(Aralia taibaiensis)则为近年建立的楤木属一新种，特产于我国中西部秦巴山区及其余脉，主要为陕西南部及西部、甘肃兰州以东、四川川北及川东北、山西中条山及宁夏六盘山区，特别在陕西太白、周至、户县、佛坪、留坝、凤县、宁强、南郑、略阳、勉县、洋县、宁陕、柞水、镇巴、紫阳、安康、平利、岚皋、旬阳、合阳、华山以及甘肃榆中、天水，四川穆坪等地有丰富的野生资源。
鉴于对楤木的皂苷成分已有较多报道，但对秦岭山脉产地的楤木及太白楤木则少见研究，而且由于不同产地的同种楤木属植物的成分常存在较大差别，因此不能简单以楤木属的功效来推论太白楤木的药效。
太白楤木（Aralia taibaiensis L）亦称楤木白皮，飞天蜈蚣七。其性平、味甘、微苦，具有驱风除湿、利水消肿、活血散瘀、止痛、健脾的功效。民间常用于风湿性关节炎，肾炎水肿，肝硬化腹水，急慢性肝炎，胃痛，淋虫，血崩，跌打损伤，痈肿等的治疗。现代研究亦表明楤木根皮对肾炎、肝炎，类风湿性关节炎等均具有良好的防治效果。
研究表明，楤木的根、茎、叶中含有多种化学成分，树皮含皂苷，可以水解成楤木皂苷元，即齐墩果酸。同时还含有鞣质，胆碱和挥发油等。种子富含油脂，含量达26%。除此之外，楤木根皮嫩芽含有天门冬氨酸、苏氨酸、丝氨酸、谷氨酸、甘氨酸、丙氨酸、缬氨酸、异亮氨酸、亮氨酸、酪氨酸、苯丙氨酸、赖氨酸、组氨酸、精氨酸等多种氨基酸和人体所需的钙、锰、铁、镍、铜、钴、锗等多种微量元素。楤木中研究最多的是皂苷类成分。其苷元主要是齐墩果酸（Oleanolic acid，I）和常春藤皂苷元（Hederagenin，II），它们经常在3位或28位与糖连接形成苷。所连接的糖主要有D-葡萄糖、D-葡萄糖醛酸、L-阿拉伯糖、D-半乳糖、L-鼠李糖和D-木糖及其衍生物。少数皂苷其葡萄糖醛酸的6位以甲酯形式存在。一般情况下，常见葡萄糖醛酸与葡萄糖、半乳糖、阿拉伯糖等形成直链或支链糖链后与3β-OH成苷，和28位羧基成酯苷的多为葡萄糖。
太白楤木具有保肝、降血糖等多种药理作用。目前太白楤木的文献报道较多，如：郭东艳，等，太白楤木不同部位皂苷类成分分析，《中药材》，2012年35卷第7期，比较太白楤木不同部位的总皂苷含量，为太白楤木的利用提供参考，其报道的方法是采用紫外分光光度法进行总皂苷含量测定，采用高效液相色谱法进行齐墩果酸含量测定。结果：太白楤木不同部位定性鉴别均能检出竹节参皂苷Iva,根皮与茎皮中均可检出太白楤木皂苷TA-16；总皂苷含量根皮、茎皮、叶子依次减小；游离齐墩果酸和总齐墩果酸含量根皮、茎皮、叶子依次减小。结论：所建方法有助于进行太白楤木不同部位的皂苷类成分定性分析及定量研究,为进一步完善太白楤木的药用标准及规范太白楤木资源的开发应用奠定基础。洪良健，楤木和太白楤木中抗糖尿病皂苷成分的研究，第四军医大学硕士论文，2012年，通过综合运用硅胶柱色谱、反相ODS柱色谱、SephadexLH-20柱色谱以及制备高效液相色谱等分离手段从楤木根皮中分离得到了10个化合物，从太白楤木根皮中分到5个化合物，通过化学方法(包括酸水解、糖衍生等)和波谱解析(包括核磁共振谱、质谱等)鉴定了这15个化合物的结构，均为三萜皂苷，对从太白楤木中分离到的5个皂苷开展了抗氧化、抗糖基化活性测试，发现它们均表现出抗氧化和抗糖基化的活性，对该类皂苷抗糖尿病构效关系进行分析，得到了较为明确的结论，楤木和太白楤木总皂苷的抗糖尿病作用可能是皂苷单体通过这些不同作用机制协同产生的。郭东艳，等，太白楤木抗肝损伤药效物质基础的初步研究，医学研究杂志，2012年41卷第10期，采用经典的系统溶剂法(极性由小到大:石油醚-氯仿-乙酸乙酯-正丁醇)依次对太白楤木提取液进行萃取,将各提取液分别灌胃给予四氯化碳(CCl4)致急性肝损伤模型小鼠,检测血清及肝组织中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、超氧化物歧化酶(SOD)的活性和丙二醛(MDA)、谷胱苷肽过氧化物酶(GSH-Px)的水平,比较各部位的抗肝损伤作用；将筛选出的活性部位用大孔吸附树脂进行分离纯化，不同浓度乙醇进行梯度洗脱，洗脱液分别灌胃给予肝损伤模型小鼠,检测血清及肝组织中ALT、AST、SOD的活性和MDA、GSH-Px的水平,比较各洗脱部位的抗肝损伤作用。结果与模型对照组比较,正丁醇部位可明显降低CCl4引起的ALT、AST、MDA升高,增加肝组织中SOD的活性和GSH-Px的水平；70%乙醇洗脱的正丁醇提取物可明显降低CCl4引起的ALT、AST、MDA升高,增加肝组织中SOD的活性和GSH-Px的水平,且洗脱液剂量与保肝作用有明显的正相关性。结论太白楤木保肝作用的药效活性物质大多存在于70%乙醇洗脱的正丁醇部位,其抗肝损伤作用的活性成分可能与该部位主要成分皂苷类有关。郭东艳，等，基于谱效相关的星点设计-效应面法优化太白楤木提取工艺，西北药学杂志，2012年27卷第5期，以乙醇体积分数、溶媒比、提取时间为自变量,各指纹峰相对于太白楤木皂苷TA-16的含量的加和为因变量,对自变量各水平进行多元线性回归及二项式拟合,用效应面法优选最佳工艺,并对结果进行预测分析。结果太白楤木最佳提取工艺为:13倍量70%乙醇,提取3次,每次60min,提取预测值与理论值偏差为-2.16%,二项式拟合复相关系数r=0.9131。结论星点设计-效应面法优化的太白楤木提取工艺方法简便,预测性较高。郭东艳，等，太白楤木总皂苷纯化工艺研究，陕西中医学院学报，2009年32卷第4期，采用大孔吸附树脂吸附法，以总皂苷为考察指标,研究树脂吸附容量、上样浓度、洗脱溶媒及其用量等工艺条件。结果通过HPD300型大孔树脂吸附后,先用4BV的去离子水水洗除杂,然后用2BV的70%的乙醇以1BV/h的速度洗脱,总皂苷纯度可达60.08%。结论此法能较好地分离纯化太白楤木总皂苷,是简便、可行的纯化方法。
目前尚无太白楤木用于防治关节炎方面的相关报道。
发明内容
本发明的技术方案是提供了太白楤木的新用途。
本发明提供了太白楤木总皂苷提取物在制备治疗关节炎的药物中的用途。
进一步优选地，所述的药物是治疗佐剂性关节炎、骨关节炎、痛风性关节炎的药物。
其中，所述的提取物中总皂苷的含量为4.68%-83.9%。
其中，所述的提取物中含有楤木皂苷A
其中，所述的大白楤木来源于五加科楤木属植物太白楤木Araliataibaiensis L的根皮。
其中，所述的药物是由太白楤木总皂苷提取物为活性成分，加上药学上可接受的辅料或辅助性成分制备而成的制剂。
其中，所述的制剂是口服制剂。
本发明还提供了该楤木皂苷A在制备治疗关节炎的药物中的用途。
其中，所述的药物是治疗佐剂性关节炎、骨关节炎、痛风性关节炎的药物。
本发明药物用于治疗佐剂性关节炎、骨关节炎、痛风性关节炎，药效明确。本发明药物属于纯天然制剂，不经有机溶剂处理，安全可靠；毒性小，长期使用无不良反应；对各种原因引起的关节炎均有预防和治疗作用。
具体实施方式
实施例1本发明太白楤木提取物的制备
取太白楤木Aralia taibaiensis L的根皮，加12倍量的水煎煮提取两次，每次0.5-2小时，过滤减压浓缩成浸膏。总皂苷含量为4.68%。
实施例2本发明太白楤木提取物的制备
取太白楤木Aralia taibaiensis L的根皮，加12倍量的50%乙醇回流提取两次，每次0.5-2小时，过滤减压浓缩成浸膏。总皂苷含量为11.56%。
实施例3本发明太白楤木提取物的制备
取太白楤木Aralia taibaiensis L的根皮，加12倍量的70%乙醇回流提取两次，每次0.5-2小时，过滤减压浓缩成浸膏。总皂苷含量为16.82%。
实施例4本发明太白楤木提取物的制备
取太白楤木Aralia taibaiensis L的根皮，加12倍量的90%乙醇回流提取两次，每次0.5-2小时，过滤减压浓缩成浸膏。总皂苷含量为12.38%。
实施例5本发明太白楤木提取物的制备
取太白楤木Aralia taibaiensis L的根皮，加12倍量的70%乙醇回流提取两次，每次0.5-2小时，过滤减压浓缩成浸膏，上HPD100大孔树脂，70%乙醇洗脱，收集洗脱液，干燥。总皂苷含量为83.9%。
实施例6太白楤木正丁醇部位单体化合物制备
取太白楤木Aralia taibaiensis L，加12倍量的70%乙醇回流提取两次，每次0.5-2小时，过滤减压浓缩成浸膏。上HPD100大孔树脂，2-4BV水洗脱除杂，2-4BV70%乙醇洗脱，收集洗脱液，减压浓缩干燥。继而采用半制备液相分离得到楤木皂苷A
分子式：C47H74O18分子量927.1
楤木皂苷A
该化合物为白色无定形粉末，Molish反应阳性，libermann-Burchard反应阳性。酸水解后薄层检查，检出有阿拉伯糖、葡萄糖、葡萄糖醛酸和苷元齐墩果酸。1H-NMRδ6.30（1H，d，J=8.0Hz），5.39（1H，s），4.96（1H，d，J=8.0Hz）示苷元连有三个糖，分别为β-D-吡喃葡萄糖、a-L-呋喃阿拉伯糖和β-D-吡喃葡萄糖醛酸的端基质子信号。13C-NMRδ122.8、144.1示苷元为齐墩果酸型五环三萜，苷元的13C-NMR化学位移与齐墩果酸比较，C3向低场位移了约10，C28向高场位移了约4，表明该两位已被苷化，为双糖链皂苷。在anomeric碳区有δ108.6、107.0、95.7三个碳信号，示苷元连有3个糖，综合分析108.6～62.2的碳信号，进一步确定这三个糖分别为a-L-呋喃阿拉伯糖、β-D-吡喃葡萄糖醛酸和β-D-吡喃葡萄糖。葡萄糖的端基碳向高场位移了约2，所以葡萄糖应接在苷元C28位上。该化合物的13C-NMR的数据与己知化合物楤木皂苷A（AralosideA)对照基本一致[1]，因此确定化合物为楤木皂苷A（AralosideA)。（1.姜永涛，徐绥绪，陈英杰，等.辽东楤木化学成分的研究[J].沈阳药学院学报，1991，8：265-268.）
Table 1The13C-NMR data of compound （δ，0=TMS，in C5D5N）
以下通过具体药效学试验证明本发明的有益效果。
试验例1 楤木总皂苷提取物、楤木皂苷A对佐剂性关节炎的影响
1、实验动物
SD大鼠，雄性，SPF级，体重200-220g。由西安交通大学动物实验中心提供，动物生产许可证号：SCXK(陕)2007-001。
2、实验药品
楤木总皂苷（由实施例5制备，总皂苷含量为83.9%）、楤木皂苷A，从太白楤木（Aralia taibaiensis L）根皮中提取。
Ⅱ型胶原蛋白(Sigma),卡介苗冻干粉(北京天坛生物制品有限公司),IL-1β、IL-6、TNF-α酶联免疫检测试剂盒（美国R&D公司）
3、动物造模与分组给药
用0.1mmol/L醋酸溶解Ⅱ型胶原蛋白(2mg/mL，4℃，过夜)，再与等量的弗氏完全佐剂混合，于冰浴中充分乳化制成佐剂，除正常组外，每只大鼠尾根部皮下多点注射胶原蛋白佐剂0.2mg。造模后14天将SD大鼠随机分随机分为5组，每组10只。各组连续灌胃给药。正常组灌服生理盐水，每日一次；连续用药4周。
4、检测指标及结果
4.1、生理状态
正常对照组大鼠精神状态良好，皮毛有光泽，活动灵活，食量正常，关节活动自如，无异常状态出现。随着饲养时间的延长，体重逐渐增加。造模大鼠在注射佐剂后2天，尾根局部出现红肿，逐渐加重，一周后达高峰，尾根部溃扬结痂。且精神萎靡，活动减少，毛发发黄，干枯，摄食减少。于第10天出现继发性免疫炎症，肢体关节部位变化，最初表现为足趾小关节部位皮肤红肿，皮温升高，大便稀，小便清。于14-17天踢关节以及软组织肿胀明显，体重增加缓慢甚至减轻，耳部出现红斑及结节，尾部出现结节，部分结节破馈，有黄色粘稠液体渗出，标志造模成功。灌服楤木总皂苷、楤木皂苷A后大鼠精神状态好转，皮毛有光泽，食量增加，关节红肿减轻，活动灵活，大、小便逐渐正常。耳部、尾部结节减少。
4.2、关节炎指数
造模14天后每周对各组大鼠进行关节炎指数评分：关节无红肿，0分；小趾关节稍肿，1分；趾关节和合足趾肿胀，2分；踝关节以下足爪肿胀，3分；踝关节在内全部足爪肿胀，4分；耳朵一个红斑记0.5分；尾巴一个结节记0.5分；前肢，一个前肢肿胀记0.5分。
结果表明：用药1周内，与同期模型组相比关节炎指数评分无明显变化。用药2周以后，用药组大鼠炎指数评分较模型组降低，与同期模型组相比差异显著（P＜0.05）
表1楤木总皂苷对佐剂性关节炎大鼠关节炎指数评分的影响
注：与模型组相比*P＜0.05
4.3、关节肿胀度
每周检测大鼠后肢足肿胀度。
肿胀度=当次后肢足容积-首次后肢足容积
结果表明：用药1周内，与同期模型组相比足肿胀无明显变化，甚至有个别加重的趋势。用药2周以后，用药组大鼠关节肿胀率较模型组降低，与同期模型组相比差异显著（P＜0.05）。
表2楤木总皂苷对佐剂性关节炎大鼠足肿胀度的影响
注：与模型组相比*P＜0.05,**p<0.01
4.4、血清炎症因子水平
用药4周后，各组大鼠均股动脉取血后处死，分离血清，用双抗体夹心酶联免疫吸附法(ELIsA)检测IL-1β、IL-6、TNFα含量。严格按试剂盒上方法进行检测。
表3楤木总皂苷对骨佐剂性关节炎大鼠血清IL-1β、IL-6、TNF-α含量的影响
注：与模型组相比*P＜0.05，**P＜0.01
4.5、滑膜病理变化
取双后肢关节浸于10%甲酸溶液48小时，剥离滑膜及软骨组织。常规切片、HE染色，光学显微镜下观察滑膜组织的病理变化情况。正常组大鼠滑膜细胞结构完整,排列整齐，无炎症细胞浸润及血管新生；模型组关节滑膜明显增厚，滑膜内大量淋巴细胞、中性粒细胞浸润，有不同程度的血管新生。用药组滑膜组织结构较模型组显著改善,滑膜细胞轻度增生，滑膜下层及血管周围未见大量淋巴细胞浸润。用药组血管新生改善明显。
试验例2楤木总皂苷、楤木皂苷A对骨关节炎的影响
1、实验动物
健康5-6月龄新西兰兔，雄性，体重2.2-2.6kg。由西安交通大学动物实验中心提供，动物生产许可证号：SCXK(陕)2007-001。
2、实验药品
戊巴比妥钠（上海新亚药业有限公司），木瓜蛋白酶（Sigma），青霉素（华北制药）
3、造模与分组给药
通过兔膝关节腔内注入木瓜蛋白酶，造成骨关节病变模型。将兔用戊巴比妥钠(30mgk/g，静脉注射)麻醉后对左后腿膝关节周围剃毛，然后用10%异丙醇消毒皮肤，轻弯曲膝关节，经关节两侧进针，将4%木瓜蛋白酶生理盐水溶液0.3ml通过骸上韧带注入兔左膝关节腔，隔3天1次，连续注射3次。术后持续1周肌注青霉素20万单位/天，以防感染。所有新西兰兔均采用常规饲养，在末次注入木瓜蛋白酶结束后2周随机处死模型组三只新西兰兔，取左膝关节显示造模成功后开始给药治疗（由实施例5制备，总皂苷含量为83.9%），连续用药4周后，各兔耳缘静脉取血2ml分离血清，－20℃保存备测，将各组新西兰兔全部处死，用0.9%氯化钠注射液0.5ml冲洗，获得动物患膝的关节冲洗液，于－20℃低温冰箱中保存待测。取正常对照组膝关节及其余各组造模左侧膝关节待病理观察。
4、检测指标及结果
4.1、一般情况
实验期间见正常组新西兰兔精神状态良好，毛色无异常变化，膝关节活动自如。造模后的各组新西兰兔均有不同程度跋行，自发活动明显减少，膝关节活动明显受限，对外界的刺激的敏感性降低。
4.2、病理观察
肉眼观察：正常组兔膝关节软骨外观呈蓝白色，色泽明亮，无裂纹、软化或缺损，触之较硬，关节液量较少，质地清澈透明。造模2周后，模型组膝关节可见滑膜肿胀增生，关节液量增多且呈泡沫混浊状，关节软骨失去光泽，发黄、色泽暗淡、关节表面欠规则。造模6周后，模型组膝关节的损害情况较2周有不同程度加重，表现为滑膜充血肿胀，关节边缘与滑膜有少许纤维性粘连，软骨面明显凹凸不平，甚至软骨歇裂缺损，用药各组比模型组软骨破坏情况明显好转。
光镜观察：常规切片，HE染色。光镜观察，正常组关节软骨表面光滑，由浅入深可分为表浅层、移行层、放射层和钙化层，软骨细胞整齐排列呈柱状，未见软骨细胞簇，潮标线完整。
造模2周模型组表现为软骨表面不光滑，深层可出现软骨细胞簇积。造模6周后模型组软骨破坏情况相比2周组不同程度加重，表现为软骨中、深层有大量簇聚软骨细胞，软骨面凹凸不平，出现裂缝，软骨剥脱，形成软骨缺损区，可见其表浅层、移行层软骨部分甚至全层缺损。与模型组组相比，各治疗组软骨破坏情况较轻，表现为软骨细胞排列相对整齐，软骨表面裂隙较浅，软骨缺损较少或轻。
4.3、血清炎症因子水平
用双抗体夹心酶联免疫吸附法(ELIsA)检测IL-1β、IL-6、TNFα含量。严格按试剂盒上方法进行检测。
表4楤木总皂苷对骨关节炎兔血清IL-1β、IL-6、TNF-α含量的影响
注：与模型组相比*P＜0.05，**P＜0.01
表5楤木总皂苷对骨关节炎关节冲洗液IL-1β、IL-6、TNF-α含量的影响
注：与模型组相比*P＜0.05，**P＜0.01
试验例3楤木总皂苷、楤木皂苷A对痛风性关节炎的影响
1、实验动物
SD大鼠，雄性，SPF级，体重180-220g。由西安交通大学动物实验中心提供，动物生产许可证号：SCXK(陕)2007-001。
2、实验药品
尿酸钠（Sigma），黄嘌呤氧化酶酶联免疫吸附测定试剂盒（美国R&D公司）
3、造模与分组给药
取250mg尿酸钠结晶加0.9%氯化钠注射溶液45ml,再加5ml吐温80,加热搅拌,配制成50尿酸钠注射悬液。除正常组外，其余各组大鼠均用戊巴比妥钠麻醉，仰卧位固定，大鼠右踝关节外侧后方穿刺，向关节腔内注入0.2ml尿酸钠混悬液,诱导痛风性关节炎模型，正常组关节腔内注射等体积生理盐水。于造模当天开始给药（由实施例5制备，总皂苷含量为83.9%），连续给药6天。第7天停止给药，早晨内毗取血，离心取血清，检测血清中肌酐、尿酸含量。用0.9%氯化钠注射液0.5ml冲洗，获得动物患膝的关节冲洗液，测定炎症因子含量。
4、检测指标及结果
4.1、血清中肌酐、尿酸含量
取血清，检测血清中肌酐、尿酸含量。
表6楤木总皂苷对痛风性关节炎大鼠血清中肌酐、尿酸含量和黄嘌呤氧化酶活性的影响
注：与模型组相比*P＜0.05，**P＜0.01
4.2、冲洗液中炎症因子含量
取冲洗液，检测冲洗液IL-1β、IL-6、PGE2含量。
表7楤木总皂苷对痛风性关节炎大鼠关节冲洗液IL-1β、IL-6、PGE2含量的影响
注：与模型组相比*P＜0.05
小结：楤木总皂苷、楤木皂苷A对多种关节炎具有良好的治疗作用。可用于类风湿性关节炎、骨关节炎、痛风性关节炎的治疗。
类风湿关节炎是一种慢性、对称性多关节炎为主要表现的自身免疫性疾病，病变呈持续、反复发作的过程，其主要病理变化为关节滑膜的慢性炎症，炎细胞浸润，滑膜血管新生和血管翳的形成，血管翳可向邻近软骨及骨组织侵蚀，导致骨质破坏，关节畸形和功能丧失。由于其病因及发病机制尚未完全清楚，至今仍无良好的治疗方法。佐剂性关节炎的关节组织病理及免疫学指标与人类风湿关节炎有许多相似之处，为目前研究类风湿关节炎及蹄选评价抗炎免疫药物的较理想动物模型型之一。本研究通过大鼠佐剂性关节炎模型，证明楤木总皂苷、楤木皂苷A可通过抑制炎症因子表达，降低佐剂性大鼠足肿胀率，调整细胞因子的网络失衡，干预免疫炎症。有效抗炎，缓解佐剂性关节炎大鼠症状。对佐剂性关节炎大鼠关节软骨破坏起到抑制作用，从而改善了佐剂性关节炎大鼠病情。结果提示：楤木总皂苷、楤木皂苷A具有减缓类风湿关节炎免疫介导炎症反应，改善滑膜血管新生和软骨破坏的作用，为其治疗类风湿关节炎提供了实验依据。
实验结果提示：楤木总皂苷、楤木皂苷A可以对机体细胞因子进行调节，从而促进软骨基质合成，抑制软骨基质分解，直接或间接改善了软骨基质代谢，促进损伤关节软骨的修复，对骨关节炎发挥治疗作用。
实验结果提示：楤木总皂苷、楤木皂苷A可以降低高尿酸血症小鼠血清中肌酐、尿酸水平，防治高尿酸血症发生。同时调节机体细胞因子，有效抗炎，缓解痛风性关节炎症状。对痛风性关节炎具有防治作用。
综上所述，本药物或保健食品可用于多种原因引起的关节炎，具有抗炎、调整细胞因子的网络失衡、改善软骨基质代谢，促进损伤关节软骨的修复等多种作用，适用于佐剂性关节炎、痛风性关节炎、骨关节炎等疾病的预防和治疗。
Claims (10)
1.太白楤木总皂苷提取物在制备治疗关节炎的药物中的用途。
2.根据权利要求1所述的用途，其特征在于：所述的药物是治疗佐剂性关节炎、骨关节炎、痛风性关节炎的药物。
3.根据权利要求1或2所述的用途，其特征在于：所述的提取物中总皂苷的含量为4.68%-83.9%。
4.根据权利要求1-3任意一项所述的用途，其特征在于：所述的提取物中含有楤木皂苷A
5.根据权利要求1-3任意一项所述的用途，其特征在于：所述的大白楤木来源于五加科楤木属植物太白楤木Aralia taibaiensis L的根皮。
6.根据权利要求1-3任意一项所述的用途，其特征在于：所述的药物是由太白楤木总皂苷提取物为活性成分，加上药学上可接受的辅料或辅助性成分制备而成的制剂。
7.根据权利要求6所述的用途，其特征在于：所述的制剂是口服制剂。
8.楤木皂苷A在制备治疗关节炎的药物中的用途。
9.根据权利要求8所述的用途，其特征在于：所述的药物是治疗佐剂性关节炎、骨关节炎、痛风性关节炎的药物。
10.一种治疗关节炎的药物组合物，其特征在于：它是由有效量的太白楤木总皂苷提取物或楤木皂苷A为活性成分，加入药学上可接受的辅料或辅助性成分制备而成的制剂。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510471921.0A CN105147749A (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的新用途 |
| CN201310504888.8A CN103520234B (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310504888.8A CN103520234B (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510471921.0A Division CN105147749A (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的新用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520234A true CN103520234A (zh) | 2014-01-22 |
| CN103520234B CN103520234B (zh) | 2015-09-23 |
Family
ID=49922821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310504888.8A Expired - Fee Related CN103520234B (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的用途 |
| CN201510471921.0A Pending CN105147749A (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的新用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510471921.0A Pending CN105147749A (zh) | 2013-10-23 | 2013-10-23 | 太白楤木总皂苷提取物的新用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103520234B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490962A (zh) * | 2014-11-28 | 2015-04-08 | 陕西中医学院 | 太白楤木总皂苷提取物的新用途 |
| CN106551963A (zh) * | 2015-09-25 | 2017-04-05 | 陕西中医药大学 | 太白楤木或其提取物的新用途 |
| CN108685930A (zh) * | 2018-06-25 | 2018-10-23 | 中央民族大学 | 一种龙牙楤木皂苷ⅳ的新用途 |
| CN112724276A (zh) * | 2021-02-01 | 2021-04-30 | 昭通学院 | 基于响应面法优化白背叶楤木茎皮多糖的超声辅助提取工艺 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519316A (zh) * | 2017-08-29 | 2017-12-29 | 宁波保税区攀峒信息科技有限公司 | 一种楤木茶油祛风膏及用法食品药膏日化品理疗药膏 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626099A (zh) * | 2003-12-11 | 2005-06-15 | 岐黄药业科技投资有限责任公司 | 治疗糖尿病的楤木提取物及楤木皂苷在治疗糖尿病中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223081B (zh) * | 2013-05-17 | 2014-10-15 | 宋志平 | 一种治疗关节炎及跌打损伤的青草油 |
-
2013
- 2013-10-23 CN CN201310504888.8A patent/CN103520234B/zh not_active Expired - Fee Related
- 2013-10-23 CN CN201510471921.0A patent/CN105147749A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626099A (zh) * | 2003-12-11 | 2005-06-15 | 岐黄药业科技投资有限责任公司 | 治疗糖尿病的楤木提取物及楤木皂苷在治疗糖尿病中的应用 |
Non-Patent Citations (4)
| Title |
|---|
| 崔春利等: "不同切制法对楤木根皮中皂苷类成分的影响", 《中国实验方剂学杂志》 * |
| 张家鑫等: "龙牙楤木皂苷类成分及药理活性研究进展", 《中草药》 * |
| 焦晓兰等: "皂苷免疫调节作用研究进展", 《中国民族民间医药》 * |
| 范妤等: "太白楤木总皂苷对白血病细胞增殖的影响", 《中药材》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490962A (zh) * | 2014-11-28 | 2015-04-08 | 陕西中医学院 | 太白楤木总皂苷提取物的新用途 |
| CN104490962B (zh) * | 2014-11-28 | 2018-03-23 | 陕西中医学院 | 太白楤木总皂苷提取物的用途 |
| CN106551963A (zh) * | 2015-09-25 | 2017-04-05 | 陕西中医药大学 | 太白楤木或其提取物的新用途 |
| CN106551963B (zh) * | 2015-09-25 | 2020-08-14 | 陕西中医药大学 | 太白楤木或其提取物的新用途 |
| CN108685930A (zh) * | 2018-06-25 | 2018-10-23 | 中央民族大学 | 一种龙牙楤木皂苷ⅳ的新用途 |
| CN112724276A (zh) * | 2021-02-01 | 2021-04-30 | 昭通学院 | 基于响应面法优化白背叶楤木茎皮多糖的超声辅助提取工艺 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520234B (zh) | 2015-09-23 |
| CN105147749A (zh) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488281B (zh) | 一种具有降血糖作用的新型纯植物复合浓缩饮液及其制法 | |
| CN103520234B (zh) | 太白楤木总皂苷提取物的用途 | |
| KR100847439B1 (ko) | 낙석등 추출물을 함유하는 염증성 질환 예방 및 치료용약제 | |
| CN101181317A (zh) | 马齿苋提取物及其制备方法和用途 | |
| Momo et al. | Antidiabetic and hypolipidemic effects of Laportea ovalifolia (Urticaceae) in alloxan induced diabetic rats. | |
| CN106074264A (zh) | 一种添加剂及包含该添加剂的化妆品 | |
| Jeyadevi et al. | Nutritional constituents and medicinal values of Momordica cymbalaria (Athalakkai)–A review | |
| CN104758404B (zh) | 一种复方三蛇粉组合物及其制备方法 | |
| CN104922173A (zh) | 簕菜提取物抑制α-葡萄糖苷酶的应用 | |
| Mittal et al. | A Critical Review on Ethnobotanical and Pharmacological Aspects of Euryale Ferox Salisb. | |
| CN110101731B (zh) | 具有防治眼部疾病的菊茎叶活性提取物及其制备方法与应用 | |
| KR101094157B1 (ko) | 식물생약재를 이용한 당뇨개선용 건강보조식품 | |
| CN103766901A (zh) | 一种穿心莲丙素在制备减肥食品或药品中的应用 | |
| CN105601707A (zh) | 一种蒲公英籽抗氧化四肽及其制备方法 | |
| CN110343186A (zh) | 一种牛大力多糖的制备方法及应用 | |
| CN105193824B (zh) | 一种灵芝三萜酸活性部位及其制备方法和应用 | |
| Fatima et al. | Effect of Leaves of Carissa spinarum Linn. on blood glucose and lipid profile in alloxan induced diabetic rats | |
| KR20090047209A (ko) | 동백나무 잎 추출물을 유효성분으로 하는 항 알레르기조성물 | |
| CN104490962B (zh) | 太白楤木总皂苷提取物的用途 | |
| CN101415432B (zh) | 用作免疫调节剂的药物组合物及其制备方法 | |
| CN106551963B (zh) | 太白楤木或其提取物的新用途 | |
| CN103110700A (zh) | 一种治疗类风湿性关节炎的水曲柳提取物 | |
| CN104257756A (zh) | 一种桑白皮脂肪油在制备降糖药物中的应用 | |
| CN103585226A (zh) | 一种毛莲菜提取物的制备方法及其应用 | |
| KR101093731B1 (ko) | 맥문동추출물을 유효성분으로 포함하는 염증성 질환 치료 및 예방용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150923 |